CBP Seizes 5,000+ Mislabeled Peptide Shipments at Cincinnati: What Makes an Import Seizable

According to a U.S. Customs and Border Protection media release from the Port of Cincinnati, officers identified a smuggling pattern beginning in December 2025 in which a shipper in China is described as having attempted to clandestinely introduce peptides — particularly active ingredients associated with Glucagon-like peptide-1 (GLP-1) compounds — into the United States. From December 2025 through March 25, 2026, CBP reported seizing the shipments involved. Per the release, the goods were concealed inside large 'master carton' boxes, each said to contain roughly 15 smaller, unmanifested, pre-labeled individual shipments addressed to the intended recipients.

CBP stated that officers identified over 300 master carton smuggling attempts, totaling about 5,000 individual peptide shipments. The release names retatrutide, semaglutide, and tirzepatide — all GLP-1-class compounds — alongside other peptides it describes as FDA-prohibited, including MOTS-C, TB10, semax, and cagrilintide. Cincinnati Port Director Eric Zizelman is quoted in the release as stating that 'noncertified or unlicensed chemicals originating from other countries and shipped into the United States presents a serious health risk to those who use them.'

According to CBP, the decisive legal fact is mis-manifestation. The release states that 'all the shipments… were mis-manifested as something other than what they contained.' A manifest is the legal declaration of what a shipment holds; when the declared contents do not match the actual contents, the merchandise is unlawfully introduced into U.S. commerce — and that is independently sufficient grounds for seizure, irrespective of whether the underlying product would have been admissible if declared honestly. U.S. customs law (19 U.S.C. § 1595a) provides authority to seize and forfeit merchandise unlawfully introduced into the United States, including goods that are smuggled or clandestinely imported, and the criminal smuggling statute (18 U.S.C. § 545) addresses knowingly importing merchandise by means of false or fraudulent documents.

The structure of the scheme reportedly compounded the exposure. Splitting one large consignment into many small pre-labeled parcels — a method sometimes associated with keeping individual entries below de minimis value thresholds or obscuring aggregate volume — is itself a pattern customs authorities treat as a red flag for evasion. Trade-law analysis of this case notes that this type of misstatement justifies seizure 'regardless of the underlying product,' and that the importer of record generally remains responsible for the accuracy of entries even when a foreign supplier or freight forwarder prepared the paperwork.

As a general matter, seizability at the border turns on one of two distinct failures: a customs-law defect in how the goods were declared and entered, or a substantive admissibility defect in the goods themselves under the regulations of an agency such as the FDA. The two are independent — a shipment can be honestly declared yet inadmissible, or admissible in substance yet seizable because it was misdeclared. Per the reporting, the Cincinnati seizure implicated both.

CBP and the FDA coordinate at ports of entry. CBP enforces the customs-declaration and smuggling provisions; the FDA determines whether a drug article may lawfully enter the United States. In the Cincinnati case, CBP noted it 'works jointly with the FDA' and indicated that the FDA had previously advised industry on the correct declaration of GLP-1 entries — meaning, per the release, the misdeclaration occurred against a backdrop of explicit guidance.

Under the Federal Food, Drug, and Cosmetic Act, a new drug may not be introduced into interstate commerce without an approved application in effect under section 505(a), codified at 21 U.S.C. § 355(a). Introducing an unapproved new drug violates sections 301(d) and 505(a) (21 U.S.C. § 331(d) and § 355(a)), and products distributed in violation of those provisions can simultaneously be misbranded under section 502 (21 U.S.C. § 352). Several of the seized compounds have no approved drug application as marketed and, on that basis, are characterized as unapproved new drugs in the import context.

Reporting indicates this is not an isolated enforcement posture. On March 31, 2026 — the same day as the Cincinnati release — the FDA published warning letters to online peptide sellers, including Gram Peptides, citing unapproved-new-drug and misbranding violations for offering compounds such as retatrutide and tirzepatide. The two named GLP-1 receptor agonists with FDA-approved branded products (semaglutide and tirzepatide) are approved only as specific finished, labeled prescription products; bulk active ingredient shipped from an overseas vendor and misdeclared at the border is a different regulatory article and does not inherit that approval.

Retatrutide, semaglutide, and tirzepatide are synthetic peptide and peptide-analog agonists acting at incretin receptors — semaglutide at the GLP-1 receptor; tirzepatide as a dual GIP/GLP-1 receptor agonist; retatrutide as an investigational triple GIP/GLP-1/glucagon receptor agonist. They are large, lipidated or otherwise modified peptides whose identity, purity, and structural integrity cannot be confirmed by appearance. The other named compounds span different classes: MOTS-C is a mitochondrial-derived peptide, cagrilintide is an amylin analog, and semax is a short ACTH(4-10)-derived peptide. CBP's release also lists a 'TB10' designation; the precise chemical identity behind that label is not well established in the public literature, though such 'TB' codes are commonly associated with thymosin-beta-4 fragment series.

Because these are reconstituted-powder or solution articles, contamination, mislabeling of one peptide as another, incorrect net peptide content, and degradation are all undetectable without analytical testing — precisely the verification gap that independent certificate-of-analysis (COA) review is designed to close. CBP itself noted that, 'given the nature of these importations, the authenticity of the products and safety of these peptides cannot be determined,' and that overseas facilities 'may not maintain standards within their manufacturing lines or labs.'

The Cincinnati action fits a broader 2026 pattern of tightened scrutiny on peptide imports. According to import-tracking analysis published by the Partnership for Safe Medicines covering the first quarter of 2026, of 127 tracked U.S. peptide import shipments, roughly 39 percent were classified as originating from manufacturers the report deemed illegitimate, while only about 12 percent of shipments were reported as stopped at the border — figures the group presents to illustrate both the volume of inbound peptide freight and the share that clears despite questionable provenance.

• Concealment method (per CBP): ~300+ master cartons, each said to hold ~15 pre-labeled parcels, totaling ~5,000 shipments.
• Seizure window: December 2025 through March 25, 2026; release published March 31, 2026.
• Origin: China; recipients reportedly pre-labeled inside the master cartons.
• Dual legal exposure described in the reporting: customs mis-manifestation (CBP) plus unapproved-new-drug status (FDA).
• Concurrent FDA warning letters published to online peptide sellers on the same date.

According to CBP, primarily because the shipments were mis-manifested — declared as something other than the peptides they contained — which is independently sufficient grounds for seizure under U.S. customs law. A second, separate ground cited is that the named compounds are unapproved new drugs under the FD&C Act, making them inadmissible on FDA grounds even apart from the misdeclaration.

As a general matter, either a customs-declaration defect or a substantive admissibility defect. Declaration defects include mis-manifestation, false invoicing, and smuggling or clandestine introduction (19 U.S.C. § 1595a; 18 U.S.C. § 545). Admissibility defects include status as an unapproved new drug (21 U.S.C. § 355(a)), misbranding (21 U.S.C. § 352), or FDA refusal of admission. The two categories are independent, and a single shipment can fail on both.

A master carton is a large outer shipping box declared as a single consignment. In the scheme described by CBP, each master carton concealed roughly 15 smaller, unmanifested parcels already pre-labeled with the addresses of the individual recipients — a structure CBP characterized as evidence of clandestine importation rather than a legitimate bulk entry.

Per the regulatory framework described here, no. Honest declaration would have removed the mis-manifestation ground, but the compounds named by CBP are characterized as unapproved new drugs as imported, so they would still face an FDA admissibility problem. Accurate declaration changes the legal theory of the seizure; it does not by itself make an unapproved drug article admissible.

Labeling alone does not override the underlying regulatory facts. Whether a shipment is admissible depends on how it is declared and whether the article meets FDA standards for entry, not on a 'research use only' marking by itself. The RUO context governs lawful handling of legitimately obtained material — it is not a customs-clearance mechanism, and a misdeclared shipment remains seizable regardless of any such label.

Independent analytical verification — reviewing a third-party certificate of analysis covering identity, net peptide content, and purity, ideally tied to a specific batch — is the documented way to confirm composition, since appearance cannot reveal contamination, substitution, or degradation. ChemVerify provides independent COA checks and source comparison for laboratory researchers.

• Are Research Peptides Legal? -> /learn/are-research-peptides-legal
• Research Use Only (RUO) Legal Status for Peptides: Complete Guide -> /learn/research-use-only-ruo-legal-status-for-peptides-complete-guide
• FDA Peptide Reclassification 2026: 14 Peptides Return to Category 1 -> /learn/fda-peptide-reclassification-2026-14-peptides-return-to-category-1
• Verify a Certificate of Analysis -> /verify
• Compare Peptide Sources -> /compare